MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Complete Genomics sets price for IPO a nose ahead of Pacific Biosciences offering

Complete Genomics sets price for IPO a nose ahead of Pacific Biosciences offering

By

GNOM, PACB logos

Complete Genomics Inc. yesterday filed for an initial public offering that could be worth up to $96.6 million, and if the popularity of a competing genome sequencing company’s stock is an indicator for its success, Complete Genomics won’t have much trouble hitting its mark.

Pacific Biosciences of California Inc. (NSDQ:PACB) entered the market today and raised $200 million in its IPO. The company is working on a whole-genome sequencing device that would deliver "real-time" observation of DNA-related processes.

The $16-per-share offering brings the total amount of money it’s raised since the Menlo Park, Calif.-based genomics firm‘s 2004 founding to $570 million, according to FierceBiotech.

In its IPO, Complete Genomics plans to offer 6 million shares at a range of $12 to $14 per share, according to a federal Securities & Exchange Commission filing.

The Mountain View, Calif.-based company is slated to set the actual IPO price the week of Nov. 8, according to Renaissance Capital, and requested the ticker symbol GNOM. The company was founded in 2005 and reported $2 million in revenue for the 12 months ending June 30. It’s working on another genome sequencing and analysis platform.

The genome sequencing market is expected to grow from $1.2 billion in 2009 to more than $3.6 billion by 2014, according to Scientia Advisors, which Pacific Biosciences cited in its IPO filing.

Healthcare IT, in addition to the pharmaceutical industry, are already heading in the direction of biomarker-based medicine, Scientia Advisors managing partner Harry Glorikian told MassDevice at Harvard Medical School’s World Health Forum in Boston in October. If a patient has positive or negative results for a particular test, there are already alarms built into healthcare IT applications that warn doctors about how certain treatments could affect the patient, said Glorikian.

“If that’s not directing the practice of medicine, I don’t know what is,” he said. “It’s supposed to be a guideline. It’s not etched in stone, but if you do something that it says you shouldn’t, ‘What was you medical rational for doing that?'” he asked.

The race to bring the cost of complete genome sequencing down has grown more and more competitive over the last couple months. Earlier this week, Helicos Biosciences Corp. (NSDQ:HLCS) amended its genome sequencing technology patent infringement lawsuit against Pacific Biosciences to include Life Technologies Corp. (NSDQ:LIFE) and Illumina Inc. (NSDQ:ILMN), two other companies trying to position themselves for the predicted exponential growth of DNA sequencing industry.

PACB shares were trading at $16.57 in midday activity.

In case you missed it

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply